

Index

A

- Adenoviral targeting, 188
- Adverse affects, 16, 42, 74, 78, 107, 132, 145, 157, 166, 169, 247, 255, 257, 259 (see also Antibody immunogenicity)
- Affinity, 8-15, 37, 56, 57, 59, 355359, 363-372
 - avidity, 14, 15
 - equilibrium constants (K_a and K_d), 9,10, 13, 355-359, 363, 370
 - rate constants (k_{ass} and k_{diss}), 13, 14, 363, 369, 370, 372
 - Scatchard analysis, 356-358, 360
- Animal models of disease
 - antigen-coated beads, 200
 - chronic relapsing experimental autoimmune encephalomyelitis (EAE), 103, 105, 109
 - NOD mice, 107,151
 - nude mice, 195, 198, 199
 - SCID mice, 89, 197
 - sepsis, 164-166
 - syngeneic tumors, 43, 88, 89, 91,200
 - transgenic mice, 152, 201
 - transplant models, see Transplantation
 - xenograft, 143
 - fetal pig neurones, 152
 - islet, 150, 151
 - liver, 150, 151
 - tumor, 42, 89, 194-200
- Antibody concentration, 319-323
- Antibody conjugates, see Immunoconjugates
- Antibody directed enzyme prodrug therapy (ADEPT), see Immunoconjugates (enzyme conjugates)
- Antibody engineering, 35-59
 - antibody modification, see also Phage display
 - chimeric antibody, 35-37, 87, 94, 121, 250
 - diabodies, 44
 - dsFv, 35
 - Fab, Fab', F(ab')₂ see antibody structure
 - fusion proteins, 40, 42, 43 (see also Immunoconjugates)
 - humanized antibody, 35, 36, 65, 66, 94, 106, 108, 126, 128, 142, 162, 163, 188, 189, 250
 - scFv, BABS, SCAB, SCA, see sFv
 - sFv, 35, 40-45, 54-58, 188, 199, 461, 465, 469
 - veneered antibody, 37
 - PCR of V regions, 35, 54, 453-458
- Antibody function, 4, 167, 168
 - agglutination, 159
 - attenuation of bacterial mediators, 159
 - Fc receptor interactions, 5
 - ADCC, 5, 16, 77, 89, 159
 - complement, 4, 5, 16, 77, 89, 158
 - alternative pathway, 4
 - classical pathway, 4

- lytic pathway, 4
 - phagocytosis, 158
- inhibition of microbial metabolism, 159
- neutralization, 4, 158
- restriction microbial mobility, 159
- Antibody genetics, 6-8
 - affinity maturation 8, 11
 - class switching, 8, 248
 - somatic mutation, 8
 - V(D)J recombination, 6, 8
- Antibody immunogenicity, 16, 64, 67
 - HAMA (human anti-mouse antibody), 16, 36, 41, 42, 125, 164, 166, 169, 213, 381-390
 - human anti-rat response, 249
 - hypersensitivity, 64, 78
 - idiotype, 37, 64, 65, 78-81, 88, 255, 381, 382, 384-388
 - idiotypic network and immunisation, 78-81
 - immuno suppression, 66
 - tolerance, 64-69
- Antibody production, 23-32, 211-213, 218, 219, 252-254, 267-279
 - antigen immunogenicity, 24, 27
 - adjuvant, 25, 268, 272
 - hapten, 25
 - immunization schedule, 26, 268, 271, 272
 - T-cell help, 24
- monoclonal, 23, 26, 27, 32, 142
 - bulk production, 30, 252-254
 - cloning, 30, 276-278
 - fusion, 28, 268, 270, 273, 274
 - hybridoma, 27, 28, 142, 144, 267, 275, 278, 284, 285
 - hypoxanthine, aminopterin and thymidine (HAT) medium, 28, 29, 268, 270, 271
 - screening, 29, 30, 268, 276-278
- polyclonal, 23, 25, 26, 32, 142
- quality control
 - aseptic technique, 313-317
 - measuring endotoxin, 309-312
 - raw materials, 295-301
 - stability, 303-307
- Antibody purification, 281-288, 289-293
 - concentration, 290
 - ion exchange, 289-293
 - precipitation, 290, 291
 - protein A/G, 281-288, 289, 319
- Antibody specificity
 - β 2 microglobulin, 150, 151
 - 72 kDa ovarian/colorectal-associated glycoprotein, 74
- adenovirus, 188
- angiotensin-converting enzyme (ACE), 183
- 17-1A (epithelial antigen), 78, 80
- B72.3 pancarcinoma antigen, 41
- C5a, 166
- CAI 25, 80
- Carcinoembryonic antigen (CEA), 41, 42, 75, 185, 198, 199, 201
- CD 18, 68,69
- CD 19, 89, 94
- CD20, 58, 85- 87, 89, 92, 94
- CD21, 89
- CD22, 89
- CD25 (1L2-R), 103, 143
- CD28, 108
- CD3/TCR, 18, 43, 44, 58, 68, 69, 77, 92, 94, 95, 107, 120, 142, 143, 145, 146, 149
- CD38, 89
- CD4, 67, 69, 106, 107, 133, 143
- CD40, 43, 89-91
- CD4OL, 68, 69
- CD45, 71, 143
- CD5, 143
- CD52, 68, 69, 71, 85, 106, 107, 243-262, see also CAMPATH-1

- CD64, 78
 CD7, 43, 103
 CD72, 89
 CD74, 89
 CD8, 67, 143
 CD80, 109
 CD86, 89, 109,
 Digoxin, 11
 DNP 38, 44
 endotoxin, 163, 164
 epidermal growth factor receptors,
 76
 E-selectin 182, 188
 Fc receptors, 18
 fibrin, 181
 folate receptor, 77
 follicle-stimulating hormone, 213
 gp120 HIV, 59, 163
 HER-2/neu proto-oncogene, 74, 78
 human high-molecular-weight,
 melanoma associated antigen
 (HHW-MAA), 79, 80
 human milk fat globulin (HMFG1),
 75
 ICAM-1, 143, 150, 183
 idiotype, 43, 44, 80, 85, 87-90, 92,
 94
 IgM, 87
 IIBIIIA fibrinogen receptor, 180
 IL1 receptor, 165, 166
 IL6, 165, 166, 168
 interferon γ , 100
 LFA, 143, 150
 lipid A, 163
 luteinizing hormone, 213
 lymphocyte, 181
 MHC class 1, 143, 150, 152, 185
 MHC class 11, 89, 103-105, 185
 MUC 1, see Polymorphic epithelial
 mucin
 myosin, 42, 186
 neutrophil, 181
 NP, 36
 OKT3 see CD3
 oncoscint, see TAG-72
 phenyl oxazoline (phOx), 55
 phosphoryl choline, 39
 placental alkaline phosphatase
 (PLAP), 76
 polyclonal antisera, 141, 157-170
 polymorphic epithelial mucin
 (MUC1), 200, 201
 P-selectin, 181
 rituximab, see CD20
 RSV fusion protein, 162
 Salmonella serotype B
 polysaccharide, 40
 TAG-72, 185
 tenascin, 76
 transferrin receptor, 43, 44, 74
 tumor antigen gp72, 80
 tumor necrosis factor (TNF), 100,
 115-133, 165, 166
 VCAM-1, 183
 Antibody structure, 1-4
 antibody classes, 5, 6
 antigen binding site, 2
 complementarity determining
 regions (CDRs), 2, 36, 37, 39,
 55-57, 79, 461, 462
 domain, 2, 36
 variable domains (V_H and V_L), 3,
 36, 37, 39, 40, 44, 45, 58,
 453, 461
 F(ab')₂, 3, 4, 35, 41, 91, 92, 107,
 149, 179, 182, 325-328, 333-
 338
 F(ab')₃, 338, 339
 Fab, 3, 4, 9, 35, 38, 41, 54, 55, 58,
 59, 78, 142, 179, 212, 328,
 336,
 Fab', 3, 4, 35, 108, 333, 338
 Fe, 3, 4, 11, 16, 38, 40, 45, 46, 90,
 91, 142, 149, 212, 335

- framework regions, 39
 - Fv, 3, 35, 38, 39, 325
 - heavy chain, 1, 6, 8
 - hypervariable regions, see
 - Complementarity determining regions
 - light chain, 1, 6, 8
 - Antigen expression, 70, 71
 - antigenic variation, 169
 - Antigen presentation
 - antigen-presenting cells 108, 109
 - dendritic cells, 148
 - macrophages, 100
 - passenger lymphocytes, 146-148, 150
 - costimulation blockade, 100, 108-110
 - CD80, 86, 28, CTLA4, CD40 see
 - Cell surface molecules
 - Apoptosis, 71, 87, 89, 90, 92 104
 - Autoimmune disease, 66, 69, 99-110, 249
 - autoimmune cytopenia, 258
 - Crohn's disease, 120, 128, 132, 182
 - diabetes mellitus type 1, 100
 - multiple sclerosis, 100, 106, 258
 - psoriasis, 106
 - rheumatoid arthritis, 100, 103, 106, 115-133, 182, 187, 257
 - scleroderma, 258
 - systemic lupus erythematosus (SLE), 106
 - uveitis, 258
 - vasculitis, 154-255, 256
- B**
- β 2 microglobulin, see Cell surface molecules
 - Biosensor, 59, 363-372, 382, 387, 388
 - Bispecific antibodies, 18, 19, 44, 77, 94, 188, 333-339
 - diabodies, see Antibody engineering
- Blood-brain barrier, 157, 168, 169, 249
- C**
- CAMPATH-1, see also Antibody specificity, CD52, 243-262
 - structure CD52, 259, 260
 - Cancer, see Neoplastic disease
 - Cardiovascular disease
 - myocardial infarct, 186
 - thrombosis, 180, 181
 - Cell surface molecules
 - β 2 microglobulin, 150-152
 - CD28, 100, 108, 109
 - CD3, 100, 107, 149
 - CD4, 33, 43, 100, 106
 - CD40, 92, 100, 108
 - CD45, 71
 - CD8, 33, 149
 - CD80 & 86, 100, 108
 - CTLA4 (CD 152), 68, 100, 108, 109
 - ICAM-1 129, 149, 150
 - LFA-1, 149
 - LFA-3, 149, 150
 - VCAM-1, 129, 130
 - Cost, 170
 - Cytokines and chemokines, 100
 - GM-CSF, 43, 117, 119, 130
 - IL1 receptor antagonist, 119, 129
 - IL1, 43, 115-117, 119, 129, 131, 132, 159, 163, 165, 166
 - IL10, 115, 116, 119, 121, 136, 259
 - IL11 136
 - IL2, 117
 - IL4, 116, 117, 121, 136
 - IL6, 117, 119, 124, 127, 129, 136, 159, 163, 165, 166
 - IL8, 119, 129, 130
 - Interferon- γ 80, 100, 115, 117, 259

MCP-1, 129, 130
TNF, 115-133, 159, 163, 165, 166, 259
 biological properties, 120
 regulation of synthesis, 121
 soluble TNF receptors, 119
 structure, 120
 TNF receptor I (p55), 120
 TNF receptor T1D75), 120
 TNF receptor-Ig fusion protein, 126
transforming growth factor- β (TGF- β), 115, 119, 121
vascular endothelial growth factor (VEGF), 130

D

Dendritic cells, see Antigen presentation
Disease (human), see Autoimmune disease, Cardiovascular disease, Inflammatory disease, Infectious disease, or Neoplastic disease,

E

Endothelium, 182
Endotoxin, 159, 163, 309-312, 298
Enzymatic cleavage, 325-331
 antibody fragments, see Antibody molecule, structure
 papain, 2, 38, 325, 327-329
 pepsin, 3, 325, 326,328

F

FACS, see Flow cytometry
Fas, see Apoptosis
Fc receptors, 5, 92, 109,
Flow cytometry, 58, 304-306, 387, 407-414

H

Hemagglutination, 319-323
HLA, see Major histocompatibility complex
HPLC, 333, 338
Human immunoglobulin, 159-161, 182, 186, 187
Hybridoma, see Antibody production
Hypoanthinephosphoribosyl transferase (HPGRT), 29

I

Idiotype, see Antibody immunogenicity
Imaging, 42, 179-189
Immunoassay, 209-223
 Detection, 215, 221
 ELISA, 10, 14, 15, 59, 216, 220, 319, 335, 373-379, 382-386, 465-467, 469
 Immobilization of antigen, 214, 215, 220
 Validation, 221, 222
Immunoconjugates, 16-18 (see also Antibody engineering, Fusion proteins)
 CD4, 43,
 cytokines, 43
 drug conjugates, 17
 enzyme conjugates 17, 18, 40, 199
 immunotoxins, 18, 43, 73
 bryodin 1, 43
 calicheamicin, 74
 diphtheria toxin, 43
 maytansinoid, 74
 Pseudomonas exotoxin, 43, 74
 ricin, 43, 74
 protein A, 43
 radioimmunoconjugates, 18, 74-77
Immunoreactivity 35 1-360
Immunostaining, 10, 14

- electron microscopy 439-451
 - immunocytochemistry, 415-436
 - Immunotoxins, see Immunoconjugates
 - Infectious diseases 120, 157-170
 - acute septic shock, 120, 127, 163, 165
 - botulism, 157
 - cytomegalovirus, 157-159, 161
 - diphtheria, 157, 161
 - Escherichia coli, 158
 - haemophilus influenzae meningitis, 157, 159, 168
 - hepatitis A and B, 157, 159, 160
 - HIV, 120, 162, 163
 - Jarisch-Herxheimer syndrome, 120, 128
 - Klebsiella pneumonia, 158
 - measles, 157, 159, 160
 - meningococcal meningitis, 157
 - mumps, 157, 161
 - polio, 157
 - Pseudomonas aeruginosa, 158
 - rabies, 157, 161
 - respiratory syncytial virus, 158, 162
 - rubella, 160
 - sepsis, 120, 163, 164
 - Streptococcus pneumonia, 167
 - tetanus, 157, 159, 161, 169
 - toxic shock syndrome, 162
 - variceila, 157, 158, 159, 160
 - Inflammatory disease, 181, 182, see also Autoimmune disease
 - adult respiratory distress syndrome, 120
 - Intellectual property, 227-237
 - copyright, 227, 228, 233-235
 - patent, 67, 227, 230, 231-233, 246
 - trademark, 227, 235, 236
 - Intracellular signalling, 71, 86-90, 92, 94, 104, 109
- L**
- Lymphokine-activated killer (LAK) cells, 74
- M**
- Macrophages, see Antigen presentation, Macrophages
 - Major histocompatibility complex (MHC) molecules, 101
 - MHC class I, 147, 149, 152
 - MHC class II, 4, 24, 25, 64, 65, 100, 105, 106, 147, 148
 - Metalloproteinases, 117, 119, 120, 131
- N**
- Neoplastic disease, 69, 70, 73-81, 183-185
 - angiogenesis, 71
 - breast, 76, 78, 185
 - colorectal, 74-80, 185, 195
 - glioma, 76, 188
 - leptomeningeal neoplasia, 74
 - leukemia, 71, 107, 247, 249
 - chronic lymphocytic leukemia, 85, 248, 249, 257
 - liver, 76
 - lung, 76
 - melanoma, 76, 79, 80, 185
 - myeloma, 186
 - lymphoma 71, 85-95, 107, 185, 249
 - Hodgkin's lymphoma 197
 - non-Hodgkin's lymphoma, 85, 86, 89, 246, 251, 257, 381
 - posttransplant lymphoma, 85
 - neuroblastoma, 76
 - osteogenic sarcoma, 74
 - ovarian, 74-78, 80, 185, 188
 - prostate, 76, 185
 - Natural killer (NK) cells, 5, 18

P

- Phage display, 53-59, 461-469
 - chain shuffling, 57
 - filamentous phage, 53, 54, 461
 - pIII (gene III product), 44, 46, 53, 56-59, 461, 465
 - pVIII, 53, 461
 - libraries
 - Cre recombinase, 56, 462
 - immunized animals, 55
 - LoxP, see Cre recombinase
 - naïve, 55
 - semisynthetic, 55, 56, 461
 - SAP, 59
 - selection, 57-59, 464-465
- Pharmacokinetics, 16, 40, 67, 103-104, 124, 168
- Polymerase chain reaction (PCR), 210
 - see also Antibody engineering
 - error-prone PCR, 57
 - PCR patent, 228
- Positron emission tomography (PET), 184
- Prostaglandins, 119

R

- Radioimmunoconjugates, see
 - Immunoconjugates
 - Radiolabeling techniques, 341-350
- indium, 342, 345

- iodine, 342, 345
 - technetium, 342, 347
 - yttrium 343, 348
- Rheumatoid factor, 212

S

- SDS-PAGE, 391-398, 469
- Signaling, see Intracellular signaling

T

- T-helper cells, 100
- Transplantation, 66-68, 103, 107, 141-153, 181
 - bone marrow, 107, 247, 258
 - cardiac, 148, 150
 - corneal, 258
 - graft-versus-host disease, 244, 247, 248
 - liver, 151
 - pancreatic islet, 145, 147, 148
 - renal, 141, 148, 151
 - skin, 150, 151

W

- Western blotting, 394, 398-404